Brigatinib (AP26113) Efficacy and Safety in ALK plus NSCLC: Phase 1/2 Trial Results

被引：0

作者：

Gettinger, Scott N. ^{[1
]}

Bazhenova, Lyudmila ^{[2
]}

Salgia, Ravi ^{[3
]}

Langer, Corey J. ^{[4
]}

Gold, Kathryn A. ^{[5
]}

Rosell, Rafael ^{[6
,7
]}

Shaw, Alice ^{[8
]}

Weiss, Glen J. ^{[9
]}

Dorer, David J. ^{[10
]}

Rivera, Victor M. ^{[10
]}

Conlan, Maureen G. ^{[10
]}

Kerstein, David ^{[10
]}

Camidge, Ross ^{[11
]}

机构：

[1] Yale Canc Ctr, New Haven, CT USA

[2] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[3] Univ Chicago Med, Chicago, IL USA

[4] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[5] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[6] Dexeus Univ Inst, Barcelona, Spain

[7] Catalan Inst Oncol, Barcelona, Spain

[8] Massachusetts Gen Hosp, Boston, MA 02114 USA

[9] Canc Treatment Ctr Amer, Goodyear, AZ USA

[10] Ariad Pharmaceut Inc, Cambridge, MA USA

[11] Univ Colorado, Ctr Canc, Aurora, CO USA

来源：

JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期

关键词：

NSCLC; TKI; brigatinib;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ORAL33.06

引用

页码：S238 / S239

页数：2

共 50 条

[21] Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK plus non-small cell lung cancer (ALTA-1L) [J].

Garcia Campelo, Maria Rosario ;

Lin, Huamao M. ;

Zhu, Yanyan ;

Perol, Maurice ;

Jahanzeb, Mohammad ;

Popat, Sanjay ;

Zhang, Pingkuan ;

Camidge, D. Ross .

LUNG CANCER, 2021, 155 :68-77

[22] Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (Pts) with ALK plus NSCLC [J].

Horn, Leora ;

Wakelee, Heather ;

Reckamp, Karen ;

Blumenschein, George ;

Infante, Jeffrey ;

Carter, Corey ;

Waqar, Saiama ;

Neal, Joel ;

Gockerman, Jon ;

Harrow, Kimberly ;

Dukart, Gary ;

Liang, Chris ;

Gibbons, James ;

Hernandez, Jennifer ;

Newman-Eerkes, Tera ;

Lim, Lee ;

Lovly, Christine .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S1159-S1159

[23] Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK plus NSCLC [J].

Lee, J. M. ;

Sepesi, B. ;

Toloza, E. M. ;

Lin, J. ;

Pass, H. I. ;

Johnson, B. E. ;

Heymach, J. V. ;

Johnson, M. L. ;

Ding, B. ;

Schulze, K. ;

Zhu, Q. ;

Ngiam, C. ;

Brandao, E. ;

Bara, I. ;

Chaft, J. .

JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) :S233-S234

[24] Efficacy and safety of autologous CIK cell therapy plus Toripalimab with or without chemotherapy in advanced NSCLC: A phase II study [J].

Zhong, Runbo ;

Chu, Tianqing ;

Xiong, Liwen ;

Shi, Chunlei ;

Zhang, Wei ;

Zhang, Xueyan ;

Yang, Xiaohua ;

Lian, Yuqing ;

Zhang, Mengqi ;

Zhong, Hua ;

Han, Baohui .

INTERNATIONAL JOURNAL OF CANCER, 2025, 157 (03) :549-558

[25] Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC : Initial Results of the Phase 2 ALK-Positive Cohort [J].

Dziadziuszko, Rafal ;

Mok, Tony ;

Peters, Solange ;

Han, Ji-Youn ;

Alatorre-Alexander, Jorge ;

Leighl, Natasha ;

Sriuranpong, Virote ;

Perol, Maurice ;

de Castro Junior, Gilberto ;

Nadal, Ernest ;

de Marinis, Filippo ;

Frontera, Osvaldo Aren ;

Tan, Daniel S. W. ;

Lee, Dae Ho ;

Kim, Hye Ryun ;

Yan, Mark ;

Riehl, Todd ;

Schleifman, Erica ;

Paul, Sarah M. ;

Mocci, Simonetta ;

Patel, Rajesh ;

Assaf, Zoe June ;

Shames, David S. ;

Mathisen, Michael S. ;

Gadgeel, Shirish M. .

JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (12) :2040-2050

[26] Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC [J].

Nishio, Makoto ;

Felip, Enriqueta ;

Orlov, Sergey ;

Park, Keunchil ;

Yu, Chong-Jen ;

Tsai, Chun-Ming ;

Cobo, Manuel ;

McKeage, Mark ;

Su, Wu-Chou ;

Mok, Tony ;

Scagliotti, Giorgio V. ;

Spigel, David R. ;

Viraswami-Appanna, Kalyanee ;

Chen, Zhe ;

Passos, Vanessa Q. ;

Shaw, Alice T. .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (04) :609-617

[27] Safety, Clinical Activity and Biomarker Results from a Phase lb Study of Erlotinib plus Atezolizumab in Advanced CrossMark NSCLC [J].

Rudin, Charles ;

Cervantes, Andres ;

Dowlati, Afshin ;

Besse, Benjamin ;

Ma, Brigette ;

Costa, Daniel ;

Schmid, Peter ;

Heist, Rebecca ;

Villaflor, Victoria ;

Sarkar, Indrani ;

Huseni, Mahrukh ;

Foster, Paul ;

O'Hear, Carol ;

Gettingeril, Scott .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) :S1302-S1303

[28] From preclinical efficacy to 2022 (36.7 months median follow -up) updated CROWN trial, lorlatinib is the preferred 1st-line treatment of advanced ALK plus NSCLC [J].

Ou, Sai-Hong Ignatius ;

Lee, Alexandria T. M. ;

Nagasaka, Misako .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 187

[29] Patient-Reported Outcomes and Safety from the Phase III ALUR Study of Alectinib vs Chemotherapy in Pre-Treated ALK plus NSCLC [J].

Mazieres, J. ;

Novello, S. ;

De Castro, J. ;

Migliorino, M. R. ;

Helland, A. ;

Dziadziuszko, R. ;

Griesinger, F. ;

Wolf, J. ;

Zeaiter, A. ;

Cardona, A. ;

Balas, B. ;

Karagiannis, T. ;

Chlistalla, M. ;

Smoljanovic, V. ;

Oh, I. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1897-S1897

[30] Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK plus Metastatic NSCLC [J].

Cho, B. C. ;

Obermannova, R. ;

Bearz, A. ;

Kim, D. ;

Orlov, S. ;

Borra, G. ;

Kim, S. ;

Postmus, P. E. ;

Laurie, S. ;

Park, K. ;

Geater, S. ;

Bettini, A. C. ;

Osborne, K. ;

Passos, V. Q. ;

Chen, Z. ;

Dziadziuszko, R. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1757-S1757

← 1 2 3 4 5 →